If you have been reading about melanocortin receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-12-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Lyophilised melanotan-2 is comparatively robust when kept dry, cold and dark, and a desiccated powder stored at minus twenty degrees Celsius or below is generally expected to retain its chemical integrity for extended periods. In solution the peptide is far less stable, with degradation proceeding through oxidation of tryptophan and histidine residues, hydrolysis adjacent to the lactam bridge, and aggregation at higher concentrations. Repeated freeze-thaw cycling accelerates loss of the parent peak. Working aliquots are therefore prepared once, held cold, and used without letting the stock return to ambient temperature.
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-melanocyte-stimulating hormone |
| Common synonyms | MT-II; melanotan 2 | No internationally accepted non-proprietary name |
| Typical presentation | Lyophilised powder in a sealed vial | Often supplied alongside a separate diluent |
| Regulatory status | Unapproved therapeutic substance | Customs seizure reported in several jurisdictions |
| Reported route in use | Subcutaneous injection | Self-administered outside clinical settings |
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Moroidin and its analogous celogentins all have activity comparable to that of vinblastine, and a third group of celogentins all have reduced activity. In contrast, stephanotic acid, a cyclic compound analogous only to the left-hand ring and containing the same Leu-His linkage, has no anti-mitotic activity. Other anti-tubulin agents used as chemotherapy agents have painful side effects known as neuropathy when the drugs are exposed to tissue. Although the exact mechanism for the cause of neuropathy is unknown, it is thought to be related to the degradation of microtubules, which are essential components of neurons.
JDTic is a selective, long-acting ("inactivating") antagonist of the κ-opioid receptor (KOR). JDTic is a 4-phenylpiperidine derivative, distantly related structurally to analgesics such as pethidine and ketobemidone, and more closely to the MOR antagonist alvimopan. In addition, it is structurally distinct from other KOR antagonists such as norbinaltorphimine. JDTic has been used to create crystal structures of KOR [ PDB: 4DJH, 6VI4].
=== Initial appearance === The first known documented instance of an attack by the Phylloxera in France was in the village of Pujaut in the department of Gard of the former province of Languedoc, in 1863. The wine makers there did not notice the aphids, just as the French colonists in America had not, but they noted the mysterious blight that was damaging their vines. The only description of the disease that was given by these wine growers was that it "reminded them distressingly of 'consumption'"(tuberculosis). The blight quickly spread throughout France, but it was several years before the cause of the disease was determined.
Sources: en.wikipedia.org
A suitable site is to be sought throughout Germany and identified by 2031. In principle, crystalline (granite), salt or clay rock types can be considered for a repository. There will be no "ideal" site. The "best possible" site will be sought. Mining areas and regions where volcanoes have been active or where there is a risk of earthquakes are excluded. Internationally, experts are advocating storage in rock formations several hundred meters below the earth's surface. This involves building a repository mine and storing the waste there. It is then permanently sealed. Geological and technical barriers surrounding the waste are designed to keep it safe for thousands of years. For example, 300 meters of rock will separate the repository from the earth's surface. It will be surrounded by a 100-meter-thick layer of granite, salt or clay. The first waste is not expected to be stored until 2050. The Federal Office for the Safety of Nuclear Waste Management (BfE) took up its activities on September 1, 2004. Its remit includes tasks relating to nuclear safety, the safety of nuclear waste management, the site selection procedure including research activities in these areas and, later on, further tasks in the area of licensing and supervision of repositories. In the USA, Yucca Mountain was initially selected as the final storage site, but this project was temporarily halted in February 2009. Yucca Mountain was the starting point for an investigation into atomic semiotics.
=== Redox-responsive nanogels === Redox-responsive nanogels generally contain crosslinks formed by disulfide bonds or specific crosslinking agents. Nanogels made of bioreducible and bifunctional monomers can also be used. In the presence of reducing agents such as glutathione, thioredoxin and peroxiredoxin, these nanogels respond by releasing their cargo. Given that these reducing agents and several others are found in larger concentrations inside cells compared to their external environment, redox-responsive nanogels are a promising strategy for targeted intracellular delivery.
During the 2012 Democratic presidential primaries, Sanders—dissatisfied with President Obama's "attempts to trade Social Security cuts for tax hikes"—reportedly considered running against him in the primaries. Sanders had previously suggested in 2011 that it was "a good idea" for someone to challenge Obama and "got so close to running a primary challenge ... that Senator Harry Reid had to intervene to stop him." In November 2013, Sanders suggested that Senator Elizabeth Warren could be president and that she might earn his backing if she ran. He added that if no progressive candidate ran, he might feel compelled to do so himself. In December 2014, Warren said she was not running. Sanders announced his intention to seek the Democratic Party's nomination for president on April 30, 2015. His campaign was officially launched on May 26 in Burlington. In his announcement, Sanders said, "I don't believe that the men and women who defended American democracy fought to create a situation where billionaires own the political process" and made this a central idea throughout his campaign. Warren welcomed Sanders's entry into the race, saying, "I'm glad to see him get out there and give his version of what leadership in this country should be", but never endorsed him. Initially considered a long shot, Sanders won 23 primaries and caucuses and around 46% of pledged delegates to Hillary Clinton's 54%. His campaign was noted for its supporters' enthusiasm, as well as for rejecting large donations from corporations, the financial industry, and any associated Super PAC.
Sources: en.wikipedia.org
19 February 2013 – SENSEX becomes S&P SENSEX as BSE ties up with Standard and Poor's to use the S&P brand for Sensex and other indices. 13 March 2014 - The SENSEX closes higher than the Hang Seng Index, to become the major Asian stock market index with the highest value, for the first time ever. 22,000, 24 March 2014 – The SENSEX on 10 March 2014 crossed the 22,000 mark for the first time during intra-day trading. However, it was on 24 March 2014 that the index finally closed above the milestone at 22,095.30. 23,000, 9 May 2014 - The SENSEX crossed record 23,000 level for the first time, but close just short of the milestone level, on 9 May 2014. The index would close well above the 23,000 mark during the following session. 12 May 2014 - The SENSEX closed at its record all-time high of 23,551, a rise of 2.42%(+556.77 points) intraday due to continued fund inflows on hopes of a stable government. 24,000, 13 May 2014 - The SENSEX crossed record 24,000 level for the first time, on 13 May 2014 and reached its peak of 24,067.11 due to sustained capital inflows by foreign funds at the domestic bourses and widespread buying by retail investors after exit polls showing the BJP-led NDA forming the government lifted the key indices to new highs. However it closed at a little low at 23,905 points 25,000, 16 May 2014 - The SENSEX crossed record 25,000 level for the first time, on 16 May 2014 and reached its peak of 25,364.71 due to winning of the BJP led NDA government by a staggering record marginal difference of all times. However, it closed well below the 25,000 mark.
=== Toxicity of sulfur compounds === When sulfur burns in air, it produces sulfur dioxide. In water, this gas produces sulfurous acid and sulfites; sulfites are antioxidants that inhibit growth of aerobic bacteria and a useful food additive in small amounts. At high concentrations these acids harm the lungs, eyes, or other tissues. In organisms without lungs such as insects, sulfite in high concentration prevents respiration. Sulfur trioxide (made by catalysis from sulfur dioxide) and sulfuric acid are similarly highly acidic and corrosive in the presence of water. Concentrated sulfuric acid is a strong dehydrating agent that can strip available water molecules and water components from sugar and organic tissue. The burning of coal and/or petroleum by industry and power plants generates sulfur dioxide (SO2) that reacts with atmospheric water and oxygen to produce sulfurous acid (H2SO3). These acids are components of acid rain, lowering the pH of soil and freshwater bodies, sometimes resulting in substantial damage to the environment and chemical weathering of statues and structures. Fuel standards increasingly require that fuel producers extract sulfur from fossil fuels to prevent acid rain formation. This extracted and refined sulfur represents a large portion of sulfur production. In coal-fired power plants, flue gases are sometimes purified. More modern power plants that use synthesis gas extract the sulfur before they burn the gas.
In 2004, John L. Helgerson, the Inspector General of the Central Intelligence Agency (CIA), conducted an internal review of the agency's pre-9/11 performance and was harshly critical of senior CIA officials for not doing everything possible to confront terrorism. According to Philip Giraldi in The American Conservative, Helgerson criticized their failure to stop two of the 9/11 hijackers, Nawaf al-Hazmi and Khalid al-Mihdhar, as they entered the United States and their failure to share information on the two men with the FBI. In May 2007, senators from both major U.S. political parties (the Republican and Democratic parties) drafted legislation to make the review public. One of the backers, Senator Ron Wyden said, "The American people have a right to know what the Central Intelligence Agency was doing in those critical months before 9/11." The report was released in 2009 by President Barack Obama.
=== Precursor to other peroxide compounds === Hydrogen peroxide is a weak acid, forming hydroperoxide or peroxide salts with many metals. It also converts metal oxides into the corresponding peroxides. For example, upon treatment with hydrogen peroxide, chromic acid (CrO3 and H2SO4) forms a blue peroxide CrO(O2)2.
Sources: en.wikipedia.org
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.
It was developed in the 1980s by researchers investigating analogues of alpha-melanocyte-stimulating hormone for pigmentation and related endpoints. Early work included small human studies during the 1990s. Development did not progress to licensing, and the compound remained a research and grey-market item.
Peptides are prone to truncation, oxidation and aggregation during synthesis and handling. Without independent testing, a buyer cannot confirm the identity or the content of a vial. Analytical surveys of unapproved peptide products have repeatedly found discrepancies between label claims and measured composition.
Solutions are best kept cold, protected from light, and buffered to a pH that limits hydrolysis. Dividing a stock into single-use aliquots avoids repeated freeze-thaw cycles, which measurably reduce the intact parent peak over time.